Jumping from Austin, Texas to Boston, Massachusetts, BioBots is about to release BioBot 1 at the 2015 Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress to be held September 8-11. The company has been diligently refining its 3D bioprinter technology after receiving feedback from researchers around the world in its nine-month beta partnership program.
“Our incredible team at BioBots is driven by the mission of engineering biology,” said Daniel Cabrera, co-founder and CEO of BioBots, in material provided to BioNews Texas. Cabrera was interviewed by BioNews Texas following the company’s success at SXSW. “To build the BioBot 1, we partnered with some of the most brilliant minds in tissue engineering, and together we’ve developed the world’s most accessible biofabrication technology.” BioBot 1 is designed to be compact, easy to use, and intuitive, with its open cartridge system that allows researchers to load the printer with pre-prepared bioink kits. The kits are designed to be suitable for crafting several tissue types and allow living cells to be added directly to the cartridges. Alternatively, researchers can use their own natural or synthetic biomaterials, dozens of which have been tested on BioBot 1.
“With the BioBot 1 comes the ability to build 3D living tissues that can be used to reduce the time and cost of developing new drugs, 3D living tissues that can be used to personalize therapies, 3D living tissues that can be implanted into patients and 3D living tissues that can be studied to explore the largest mystery of our generation – life,” said Cabrera. Now, more researchers around the world will have access to 3D bioprinting technology because BioBot 1 is relatively less expensive than currently available 3D printers, and the level of technical expertise required to craft a 3D tissue with BioBot 1 is lower than that required by similar devices.
BioBots’ beta community has been testing the technology since earlier this year. “We can’t wait to see what else people will build now that a BioBot will sit on every lab bench around the world,” said Cabrera. Researchers at Stanford, Penn, MIT, and Drexel have been testing the technology and have created tissues such as bone, liver, and brain. “We have spent the last year listening to our community and painstakingly deciding what features were most important to making the next generation of living tissues in the lab,” said co-founder and CTO Ricky Solorzano. “The result is the best 3D bioprinter in the world – the BioBot 1.”
In addition to BioBot, the most widely used bioink used in the field, BioGel, will be released by BioBots. It is a gelatin methacrylate-based solution that has been extensively characterized and tested for the specialized tissues that can be produced by BioBot 1. “We hit a perfect balance between versatility and accessibility,” said Solorzano. “While being a very open system to allow users to input a wide range of materials and cell types, it still remains easy to use.” After September 8th, researchers around the world will be able to order BioBot 1 for a price of $10,000.
BioBots creates high-resolution desktop 3D bioprinters and bioinks capable of producing functional three-dimensional living tissues. Built to reduce the high costs of traditional 3D bioprinting systems, the accessibility to researchers and flexible open system architecture for construct design is making BioBots the platform of choice for leading bioengineering laboratories around the world. BioBots was founded in 2014 by University of Pennsylvania graduates Daniel Cabrera and Ricardo Solorzano, and is funded by DreamIt Health, 500 StartUps, and Ben Franklin Tech Partners.
About BioBot 1
BioBot 1 comprises a number of innovations that are unique within the desktop bioprinting space. Its patented visible light technology makes it the only printer of this type capable of curing biomaterials with safe visible light, allowing researchers to generate precise 3D tissue constructs while preserving cell viability. Its dual-purpose heated extruder can mimic natural body temperature to protect cells from environmental stressors during printing, as well as cure thermoplastic support materials within safe temperature ranges for greater material flexibility. In an enhancement to its beta release, the BioBot 1 includes a dynamic dual-extruder system, allowing researchers to deposit multiple materials interchangeably within the same sample, enabling for greater print complexity, faster print times, and greater diversity of biomaterials to be used in the tissue construct.